Company intelligence / Profile preview
Synklino
Capital Region of Denmark, Denmarksynklino.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Synklino is developing SYN002, a drug candidate that eliminates both lytic and latently infected cells to eradicate cytomegalovirus (CMV) infections in transplant recipients. The drug works by targeting CMV US28 and is currently in preclinical development.[3][5]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Fusion protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Synklino.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synklino.